These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30152525)

  • 21. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group.
    Sotlar K; George TI; Kluin P; Reiter A; Schwaab J; Panse J; Brockow K; Hartmann K; Sperr WR; Kristensen T; Nedoszytko B; Carter M; Bonadonna P; Lyons JJ; Kluin-Nelemans HC; Hermine O; Akin C; Broesby-Olsen S; Hoermann G; Triggiani M; Butterfield JH; Jawhar M; Gotlib J; Metcalfe DD; Orfao A; Arock M; Valent P; Horny HP
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1986-1998.e2. PubMed ID: 35724949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2012 Apr; 87(4):401-11. PubMed ID: 22410759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
    Damaj G; Joris M; Chandesris O; Hanssens K; Soucie E; Canioni D; Kolb B; Durieu I; Gyan E; Livideanu C; Chèze S; Diouf M; Garidi R; Georgin-Lavialle S; Asnafi V; Lhermitte L; Lavigne C; Launay D; Arock M; Lortholary O; Dubreuil P; Hermine O
    PLoS One; 2014; 9(1):e85362. PubMed ID: 24465546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
    Singh A; Al-Kali A; Begna KH; Litzow MR; Larsen JT; Sher T; Abdelmagid MG; Farrukh F; Reichard KK; Gangat N; Pardanani A; Tefferi A
    Am J Hematol; 2022 May; 97(5):630-637. PubMed ID: 35156231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relevant updates in systemic mastocytosis.
    Coltoff A; Mascarenhas J
    Leuk Res; 2019 Jun; 81():10-18. PubMed ID: 30978435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.
    Lim KH; Tefferi A; Lasho TL; Finke C; Patnaik M; Butterfield JH; McClure RF; Li CY; Pardanani A
    Blood; 2009 Jun; 113(23):5727-36. PubMed ID: 19363219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aggressive systemic mastocytosis with the co-occurrence of PRKG2::PDGFRB, KAT6A::NCOA2, and RXRA::NOTCH1 fusion transcripts and a heterozygous RUNX1 frameshift mutation.
    Poscente M; Tolomeo D; Arshadi A; Agostini A; L'Abbate A; Solimando AG; Palumbo O; Carella M; Palumbo P; González T; Hernández-Rivas JM; Bassi L; Isidori R; Dell'Aquila M; Trapè G; Latagliata R; Pessina G; Natoni F; Storlazzi CT
    Cancer Genet; 2024 Jun; 284-285():5-11. PubMed ID: 38471404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
    Pardanani A; Reichard K; Tefferi A
    Br J Haematol; 2024 Feb; 204(2):402-414. PubMed ID: 38054381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies.
    Pardanani A; Lim KH; Lasho TL; Finke C; McClure RF; Li CY; Tefferi A
    Blood; 2009 Oct; 114(18):3769-72. PubMed ID: 19713463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis.
    Nwogbo OV; Fang H; Wang W; Xu J; Miranda RN; Bose P; Ok CY; Jorgensen JL; Medeiros LJ; Wang SA
    Am J Clin Pathol; 2024 Jun; 161(6):598-608. PubMed ID: 38372648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022.
    Arock M; Hoermann G; Sotlar K; Hermine O; Sperr WR; Hartmann K; Brockow K; Akin C; Triggiani M; Broesby-Olsen S; Reiter A; Gotlib J; Horny HP; Orfao A; Metcalfe DD; Valent P
    J Allergy Clin Immunol; 2022 Jun; 149(6):1855-1865. PubMed ID: 35430191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.
    Jawhar M; Schwaab J; Hausmann D; Clemens J; Naumann N; Henzler T; Horny HP; Sotlar K; Schoenberg SO; Cross NC; Fabarius A; Hofmann WK; Valent P; Metzgeroth G; Reiter A
    Leukemia; 2016 Dec; 30(12):2342-2350. PubMed ID: 27416984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical Staining to Identify Concomitant Systemic Mastocytosis in Acute Myeloid Leukemia with
    Hwang SM; Kim BJ; Lee JS; Seong MW; Seo SH; Paik JH; Kim SA; Lee JY; Lee JO; Chang YH; Bang SM
    Ann Lab Med; 2022 Nov; 42(6):678-682. PubMed ID: 35765876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification.
    Trizuljak J; Sperr WR; Nekvindová L; Elberink HO; Gleixner KV; Gorska A; Lange M; Hartmann K; Illerhaus A; Bonifacio M; Perkins C; Elena C; Malcovati L; Fortina AB; Shoumariyeh K; Jawhar M; Zanotti R; Bonadonna P; Caroppo F; Zink A; Triggiani M; Parente R; von Bubnoff N; Yavuz AS; Hägglund H; Mattsson M; Panse J; Jäkel N; Kilbertus A; Hermine O; Arock M; Fuchs D; Sabato V; Brockow K; Bretterklieber A; Niedoszytko M; van Anrooij B; Reiter A; Gotlib J; Kluin-Nelemans HC; Mayer J; Doubek M; Valent P
    Allergy; 2020 Aug; 75(8):1927-1938. PubMed ID: 32108361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on diagnostic approaches and therapeutic strategies in systemic mastocytosis.
    Radia DH; Moonim MT
    Best Pract Res Clin Haematol; 2022 Jun; 35(2):101380. PubMed ID: 36333068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management.
    Pardanani A
    Am J Hematol; 2016 Nov; 91(11):1146-1159. PubMed ID: 27762455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive mutational profiling in advanced systemic mastocytosis.
    Schwaab J; Schnittger S; Sotlar K; Walz C; Fabarius A; Pfirrmann M; Kohlmann A; Grossmann V; Meggendorfer M; Horny HP; Valent P; Jawhar M; Teichmann M; Metzgeroth G; Erben P; Ernst T; Hochhaus A; Haferlach T; Hofmann WK; Cross NC; Reiter A
    Blood; 2013 Oct; 122(14):2460-6. PubMed ID: 23958953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.